Loren Stefan 4

What Happened
Loren Stefan, a consultant to Cellectar Biosciences (CLRB), was granted a derivative award on 2026-07-08 for 15,000 shares (transaction code A). The grant was reported with $0.00 cash paid. The filing describes the award as an option that will vest in full on July 8, 2027, subject to Stefan’s continued service through the vesting date.

Key Details

• Transaction date: 2026-07-08; recorded as a grant/award (code A).
• Shares/options granted: 15,000 (derivative interest); consideration reported: $0.00.
• Vesting: “This option shall vest in full on July 8, 2027,” contingent on continued service (footnote).
• Exercise price / other option economics: not specified in the provided Form 4 details.
• Shares owned after transaction: not reported in the summary provided.
• Filing timeliness: Form 4 filed on 2026-07-08 (same day as transaction), indicating a timely report.

Context
This is a derivative option grant, not an open-market purchase or sale — no shares were sold or bought immediately and no cash changed hands at grant. If the consultant remains with the company through the vesting date, the option will vest and then may be exercisable under the option’s terms (exercise price and other terms not disclosed here). Grants to consultants are common compensation; they reflect compensation arrangements rather than an immediate insider market view.